Scarica l'app Stockscreener
43.59
0.80%
-0.35
Dopo l'orario di chiusura:
43.62
0.03
+0.07%
Precedente Chiudi:
$43.94
Aprire:
$43.86
Volume 24 ore:
2.02M
Relative Volume:
1.22
Capitalizzazione di mercato:
$5.66B
Reddito:
-
Utile/perdita netta:
$-507.65M
Rapporto P/E:
-9.4761
EPS:
-4.6
Flusso di cassa netto:
$-616.24M
1 W Prestazione:
+3.81%
1M Prestazione:
+39.58%
6M Prestazione:
+49.69%
1 anno Prestazione:
-63.04%
Intervallo 1D:
$42.80
$44.39
Intervallo di 1 settimana:
$41.29
$45.27
Portata 52W:
$27.66
$118.54
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Confronta PCVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
43.59 | 5.56B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-12 | Iniziato | Goldman | Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
Using data tools to time your Vaxcyte Inc. exitWeekly Trend Summary & Community Shared Stock Ideas - newser.com
Analyzing net buyer seller activity in Vaxcyte Inc.July 2025 EndofMonth & Accurate Entry/Exit Alerts - newser.com
What MACD signals say about Vaxcyte Inc.Quarterly Market Summary & AI Enhanced Execution Alerts - newser.com
Custom strategy builders for tracking Vaxcyte Inc.Entry Point & Short-Term Trading Opportunity Alerts - newser.com
Will Vaxcyte Inc. price bounce be sustainablePortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
What high frequency data says about Vaxcyte Inc.July 2025 Opening Moves & Weekly Momentum Stock Picks - newser.com
Applying sector rotation models to Vaxcyte Inc.Earnings Risk Summary & Smart Investment Allocation Insights - newser.com
How to integrate Vaxcyte Inc. into portfolio analysis toolsOptions Play & Weekly Breakout Watchlists - newser.com
Vaxcyte, Inc. (PCVX) Stock Analysis: A Promising 143% Upside Potential for Biotech Investors - DirectorsTalk Interviews
Can Vaxcyte Inc. (5VA) stock sustain double digit ROE2025 Market Overview & Daily Risk Controlled Trade Plans - newser.com
Vaxcyte (NASDAQ:PCVX) Shares Up 4.6%Time to Buy? - MarketBeat
Is Vaxcyte Inc a good long term investmentExit Strategy Tips & Turn Market Volatility into Wealth - earlytimes.in
Is Vaxcyte Inc. (5VA) stock cheap by valuation metricsQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
Will Vaxcyte Inc. see short term momentumMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com
Why Vaxcyte Inc. (5VA) stock is a strong analyst pickJuly 2025 Setups & AI Enhanced Trading Signals - newser.com
Thermo Fisher Scientific’s Valuation: Assessing the Impact of Its $1 Billion Vaxcyte Vaccine Manufacturing Deal - Yahoo Finance
Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) - Yahoo Finance
What consensus target says about Vaxcyte Inc. (5VA) stockBuy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Vaxcyte Inc. (5VA) stock sustain dividend payouts2025 Retail Activity & Safe Entry Point Alerts - newser.com
111 Capital Takes Position in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX Stock Price and Chart — NASDAQ:PCVX - TradingView
Will breakout in Vaxcyte Inc. lead to full recoveryExit Point & Reliable Price Breakout Alerts - newser.com
Is Vaxcyte Inc. (5VA) stock attractive post correctionJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - newser.com
What candlestick patterns are forming on Vaxcyte Inc.2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
Vaxcyte’s Strategic Moves: Impact on PCVX - StocksToTrade
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $134 - 富途牛牛
Why Vaxcyte Inc. stock is in analyst buy zoneWeekly Earnings Recap & Safe Entry Point Identification - newser.com
Earnings visualization tools for Vaxcyte Inc.Swing Trade & AI Driven Stock Price Forecasts - newser.com
A Look at Vaxcyte’s (PCVX) Valuation Following $1 Billion Thermo Fisher Manufacturing Deal - simplywall.st
Vaxcyte Inc.’s volatility index tracking explainedWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Is Vaxcyte Inc. (5VA) stock a buy before earnings results2025 Historical Comparison & Growth Oriented Trade Recommendations - newser.com
Vaxcyte teams up with Thermo Fisher to ensure future vaccine production - MSN
What analysts say about Vaxcyte Inc 5VA stockMarket Rumors and News & Collaborate and Win Together - earlytimes.in
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vaxcyte Inc Azioni (PCVX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):